|
|
TherapeuticsMD Announces Third Quarter 2022 Financial Results
|
|
|
TherapeuticsMD Announces Additional $7 Million Private Placement
|
|
|
TherapeuticsMD Announces $7 Million Private Placement
|
|
|
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
|
|
|
TherapeuticsMD Announces Second Quarter 2022 Financial Results
|
|
|
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
|
|
|
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
|
|
|
TherapeuticsMD Announces Expiration of Tender Offer
|
|
|
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
|
|
|
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
|
|
|
TherapeuticsMD Announces First Quarter 2022 Financial Results
|
|
|
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
|
|
|
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
|
|
|
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
|
|
|
TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx
|
|
|
TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022
|
